Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7719MR)

This product GTTS-WQ7719MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7719MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9590MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ9856MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ14373MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ2828MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ13148MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ2192MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ2446MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ14486MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW